Document:

EX-10.1

 Exhibit 10.1 
  

					
	 

  
	 		 	
	 		 	 Walgreens Boots Alliance, Inc.
 102 Wilmot
Road
 Deerfield, IL 60015
 wba.com

 February 4, 2019 
 Heather
Dixon 
 Dear Heather, 
 We are pleased to offer you the
position of Senior Vice President, Global Controller, reporting to James Kehoe, Executive Vice President and Global Chief Financial Officer. We look forward to you joining our team. As a U.S.-based team member working at the Walgreens Boots Alliance
(“WBA”) group level, your employer for payroll, benefits and tax (W-2) purposes will be within the Walgreen Co. U.S. family of companies. The terms of this offer are subject to the final approval of
the Compensation Committee of the Board of Directors of WBA. Below are the terms of your offer: 
 Base Salary. Your salary will be at the annualized
rate of $550,000, less all applicable tax withholdings and benefit deductions – paid monthly in accordance with our salaried employee payroll cycle. 

Annual Bonus Opportunity. Based on your position, you will be eligible for annual bonuses under the WBA corporate bonus program, which is based on the
Company’s fiscal year running from September 1 through August 31. You will be eligible for a pro-rated bonus for the remainder of the current fiscal year. The current bonus target for your position
is 70% of your eligible earnings. Your actual bonus each year is subject to Company performance and your individual performance, and all bonuses are subject to the discretion and approval of the Compensation Committee of the WBA Board of Directors.

 Long-Term Incentives. You will also be eligible for long-term incentives granted under the terms and conditions of the WBA 2013 Omnibus Incentive
Plan. You will be eligible for market-competitive award levels granted at the discretion of the Compensation Committee of the WBA Board of Directors. For your position, long-term incentives currently consist of the programs listed below and a
combined target award equal in economic value to $700,000 annually. You will receive your first awards on the next annual grant date following your hire date, subject to approval by the Compensation Committee of the WBA Board of Directors. As shown
below, the allocation among the two types of awards is roughly 30% in stock options and 70% in performance shares. In making award decisions each year, the Compensation Committee considers target award levels, budget levels, relative individual
performance, and other factors. 
 Stock Options: Stock options are currently awarded annually.
One-third of the award vests each year for three years after the grant date and may be exercised up to 10 years after the grant date. Stock options currently make up 30% of your total annual target award value
described above. 
  

 

 
 Performance Shares: The performance share program provides an award of contingent shares with each
year’s grant. Contingent shares are earned and settled in shares of WBA stock at the end of a three-year performance period, and the final award is based on the performance of the Company over that three-year period. Performance shares
currently make up 70% of your total target award value described above. 
 The annual and long-term incentives described above, including program
components and target award levels, are subject to adjustments over time, as we continually review our program features to align with market practices and other total rewards objectives. 

Other Employee Benefits. See the attached “Overview of Management Benefits,” briefly describing the employee benefits that are applicable.

 Relocation. You will be eligible for relocation benefits in accordance with Company policy for management employees. 

Non-Compete. As a condition to this offer of employment, and in consideration of your employment with the
Company and certain compensation and benefits provided hereunder, you will be required to sign a Non-Competition, Non-Solicitation and Confidentiality Agreement when you
begin employment. This is a standard agreement, with certain terms tailored to your area and position. A copy of this Agreement can be provided in advance upon request. A similar agreement may also be included as part of stock option award
agreements. 
 Other Compensation. To assist with your transition to the new role, you will receive the following
sign-on incentive: 
  

	 	•	 	 You will receive a one-time
sign-on bonus of $15,000. This will be paid as soon as practicable following your first day of employment and will be subject to normal tax withholdings. 

Your start date is to be determined. On your start date, please bring proof of your identity and eligibility for employment, a list of acceptable documents is
enclosed. 
 Our offer of employment will remain open for seven days from the date of this letter, and is contingent on your passing a pre-employment applicant background check and a pre-employment drug screen under our Drug Free Work Place Policy. It is our policy that the
pre-employment drug screen test be completed within 48 hours of receiving this offer packet. You can find your nearest drug testing location by calling 1-800-877-7484 or at questdiagnostics.com. Enclosed are the “Forensic Drug Testing Custody and Control Form” and the “Drug Test Consent/Release
Form”. Please complete and return the consent/release form with the offer letter. Please bring the Forensic Drug Testing Custody and Control Form with you to the drug test facility along with a valid photo I.D. accepted by the state. 

 

 
 If you want to accept this offer of employment, please sign your name on the line below, fill in the date, and return the
signed letter in the enclosed envelope. The duplicate of this letter is for your records. By signing below, you are confirming that no actual breach, threatened breach or other violation of any past, current or contemplated oral or written
contractual arrangement to which you are a party (including, but not limited to, any non-compete, non-solicitation or confidentiality agreement with any former employer)
has or will occur by virtue of your acceptance of this offer of employment or your performing services for WBA. Failure to comply can result in the rescission of this offer or termination of employment. 

You should not consider our offer of employment to be a contract or guarantee of indefinite employment. Employment at the Company is at will, for no definite
term, and is subject to Company policies, which can be changed from time to time. 
 If you have any questions please call me at +44 (0) 7469 409281. 

Sincerely, 
 /s/ Lisa Hare 

Lisa Hare 
 Vice President, Global Talent Acquisition 

Walgreens Boots Alliance 

Enclosures 

cc: James Kehoe 

I accept the offer of employment and understand that the offer is not intended to be a guarantee of continued employment.

 Name: /s/ Heather
Dixon                                        
         Date: Feb. 4, 2019HANCOCK
JAFFE LABORATORIES, INC.

AMENDED AND RESTATED 2016 OMNIBUS INCENTIVE PLAN

 

Stock
Option Grant

 

FOR
GOOD AND VALUABLE CONSIDERATION, Hancock Jaffe Laboratories, Inc. (the “Company”) hereby grants, pursuant to
the provisions of the Hancock Jaffe Laboratories, Inc. Amended and Restated 2016 Omnibus Incentive Plan (as amended, the “Plan”),
to the Grantee designated in this Stock Option Grant (the “Award Agreement”) [an Incentive/a Non-qualified]
Stock Option (the “Option”) to purchase the number of Shares set forth below, subject to certain terms and
conditions as outlined herein. Any capitalized term not otherwise defined in the Award Agreement shall have the definition set
forth in the Plan.

 

1.
General Terms of Grant.

 

	Grantee:	 	[Name]
	 	 	 
	Type
    of Option:	 	[Incentive/Non-qualified]
    Stock Option
	 	 	 
	Grant
    Date:	 	[Date]
	 	 	 
	Number
    of Shares Purchasable:	 	[####]
	 	 	 
	Option
    Price per Share:	 	$[#.##],
    which is the Fair Market Value as of the Grant Date1
	 	 	 
	Expiration
    Date:	 	[Date],
    which is [10] years from the Grant Date2
	 	 	 
	Exercisability
    Schedule:	 	[Insert
        schedule - time-based or performance-based]

        [Notwithstanding
        the foregoing Exercisability Schedule, exercisability of all or some portion of the Option may be accelerated in accordance
        with the terms and conditions set forth in this Award Agreement and the Plan.]

	 	 	 
	Exercise
    after Separation from Service:	 	Separation
        from Service for any reason other than death, Disability or Cause: any non-exercisable portion of the Option expires
        immediately and any exercisable portion of the Option remains exercisable for [90 days] following Separation from Service
        for any reason other than death, Disability or Cause.

        Separation
        from Service due to death or Disability: any non-exercisable portion of the Option expires immediately and any exercisable
        portion of the Option remains exercisable for [12 months] following Separation from Service due to death or Disability.

        Separation
        from Service for Cause: the entire Option, including any exercisable and non-exercisable portion, expires immediately
        upon Separation from Service for Cause.

        In
        no event may THE Option be exercised after the Expiration Date as provided above.

	 	 	 
	Change
    in Control:	 	[State
    the impact of a change in control upon the restricted stock award. The plan provides flexibility to the board to provide for
    one or more of the following: (i) accelerate vesting of the restricted stock award, (ii) cause for the assumption, continuation
    or substitution of the restricted stock award or (iii) cash-out the restricted stock award. See Section 15.2 in the plan.]

 

 

1
110% of FMV if an ISO is granted to a 10% shareholder

2
5 year max if an ISO is granted to a 10% shareholder

 

    	 

    	 

    

 

2.
Grant of Option. The Option granted to the Grantee is subject to the terms and conditions of the Plan. The terms and conditions
of the Plan are hereby incorporated herein by reference. Except as otherwise expressly set forth herein, the Award Agreement shall
be construed in accordance with the terms and conditions of the Plan. [The Committee has approved the grant to the Grantee of
the Option, conditioned upon the Grantee’s acceptance of the terms and conditions of the Award Agreement within 60 days
after the Award Agreement is presented to the Grantee for review.] If designated herein as an Incentive Stock Option, the Option
is intended to qualify as an Incentive Stock Option. To the extent that the Option fails to meet the requirements of an Incentive
Stock Option or is not designated as an Incentive Stock Option, the Option shall be treated as a Non-qualified Stock Option.

 

3.
Exercise of Option.

 

a.
Right to Exercise. The Option shall be exercisable, in whole or in part, during its term in accordance with the Exercisability
Schedule set forth herein and in accordance with the applicable provisions of the Plan. No Shares shall be issued pursuant to
the exercise of the Option unless the issuance and exercise comply with applicable laws. Assuming such compliance, for income
tax purposes the Shares shall be considered transferred to the Grantee on the date on which the Option is exercised with respect
to such Shares. Until such time as the Option has been duly exercised and Shares have been delivered, the Grantee shall not be
entitled to exercise any voting rights with respect to such Shares, shall not be entitled to receive dividends or other distributions
with respect thereto and shall not have any other rights of a Stockholder with respect thereto.

 

b.
Method of Exercise. The Grantee may exercise the Option by delivering an exercise notice in a form approved by the Company
(the “Exercise Notice”), which shall state the election to exercise the Option, the number of Shares with respect
to which the Option is being exercised, and such other representations and agreements as may be required by the Company. The Exercise
Notice shall be accompanied by payment of the aggregate Option Price as to all Shares exercised. The Option shall be deemed to
be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Option Price (as
well as any applicable withholding or other taxes).

 

c.
Acceleration of Exercisability under Certain Circumstances. The exercisability of the Option shall not be accelerated under
any circumstances, except as otherwise provided in the Plan; provided, however, that the Option shall become fully
vested and exercisable in the event of disability or death of the optionee [or immediately prior to, and contingent upon, a Change
in Control.]3

 

4.
Method of Payment. If the Grantee elects to exercise the Option by submitting an Exercise Notice in accordance with Section
3(b) above, the aggregate Option Price (as well as any applicable withholding or other taxes) shall be paid by cash or check;
provided, however, that the Committee may,4 but is not required to, consent to payment in any of the following
forms, or a combination of them:

 

a.
cash or check;

 

b.
a “net exercise” under which the Company reduces the number of Shares issued upon exercise by the largest whole number
of Shares with a Fair Market Value that does not exceed the aggregate Option Price and any applicable withholding, or such other
consideration received by the Company under a cashless exercise program approved by the Company in connection with the Plan;5

 

 

3
See change in control above.

4
Consider whether this determination should be made in advance of issuance.

5
Consider that the company will not be able to sell the shares directly into market to cover withholding taxes so the company
will either have to come out of pocket to pay the taxes or do a separate offering pursuant to which the proceeds will be used
to pay the taxes. An alternative is to appoint a plan administrator that can receive the (registered) shares on behalf of the
grantee, can sell a sufficient number of shares into the market to pay the exercise price and any withholding, and then send the
money back to the company while holding the remaining shares in the account of the grantee. If you go this route, keep in mind
that grantee will only be able to exercise and sell during an open trading window or pursuant to a 10b5-1 plan.

 

    	 

    	 

    

 

c.
surrender of other Shares owned by the Grantee that have a Fair Market Value on the date of surrender equal to the aggregate Option
Price of the exercised Shares and any applicable withholding; or

 

d.
any other consideration that the Committee deems appropriate and in compliance with applicable law.

 

5.
Restrictions on Exercise. The Option may not be exercised until such time as the Plan has been approved by the Stockholders,6
or if the issuance of the Shares upon exercise or the method of payment of consideration for those Shares would constitute
a violation of any applicable law, regulation or Company policy.

 

6.
Transferability. The Option may not be transferred in any manner other than by will or by the laws of descent or distribution
and may be exercised during the lifetime of the Grantee only by the Grantee; provided, however, that the Grantee
may transfer the Option (a) pursuant to a domestic relations order by a court of competent jurisdiction or (b) to any Family Member
of the Grantee in accordance with Section 17.11.2 of the Plan (entitled “Family Transfers,” or any successor provision
thereto) by delivering to the Company a notice of assignment in a form acceptable to the Company. No transfer or assignment of
the Option to or on behalf of a Family Member under this Section 6 shall be effective until the Company has acknowledged such
transfer or assignment in writing.

 

7.
Withholding.

 

a.
The Committee shall determine the amount of any withholding or other tax required by law to be withheld or paid by the Company
with respect to any income recognized by the Grantee with respect to the Option.

 

b.
The Grantee shall be required to meet any applicable tax withholding obligation in accordance with the provisions of Section 17.3
of the Plan (entitled “Tax Withholding,” or any successor provision thereto).

 

c.
Subject to any rules prescribed by the Committee, the Grantee shall have the right to elect to meet any withholding requirement
(i) by having withheld from the Option at the appropriate time that number of whole Shares whose Fair Market Value is equal to
the amount of any taxes required to be withheld with respect to the Option, (ii) by direct payment to the Company in cash of the
amount of any taxes required to be withheld with respect to the Option or (iii) by a combination of Shares and cash.

 

d.
If the Grantee makes any disposition of Shares delivered pursuant to the exercise of an Incentive Stock Option under the circumstances
described in Code Section 421(b) (relating to certain disqualifying dispositions), the Grantee shall notify the Company of such
disposition within 10 days of such disposition.

 

8.
Adjustment. Upon any event described in Section 15 of the Plan (entitled “Effect of Changes in Capitalization,”
or any successor provision thereto) occurring after the Grant Date, the adjustment provisions as provided for under Section 15
of the Plan shall apply to the Option.

 

9.
Bound by Plan and Committee Decisions. By accepting the Option, the Grantee acknowledges that the Grantee has received
a copy of the Plan, has had an opportunity to review the Plan, and agrees to be bound by all of the terms and conditions of the
Plan. In the event of any conflict between the provisions of the Award Agreement and the Plan, the provisions of the Plan shall
control. The authority to manage and control the operation and administration of the Award Agreement and the Plan shall be vested
in the Committee, and the Committee shall have all powers with respect to the Award Agreement as it has with respect to the Plan.
Any interpretation of the Award Agreement or the Plan by the Committee and any decision made by the Committee with respect to
the Award Agreement or the Plan shall be final and binding on all persons.

 

 

6
Has the plan been approved by shareholders?

 

    	 

    	 

    

 

10.
Grantee Representations. The Grantee hereby represents to the Company that the Grantee has read and fully understands the
provisions of the Award Agreement and the Plan and that the Grantee’s decision to participate in the Plan is completely
voluntary. Further, the Grantee acknowledges that the Grantee is relying solely on his or her own advisors with respect to the
tax consequences of the Option.

 

11.
Regulatory Limitations on Exercises. Notwithstanding the other provisions of the Award Agreement, the Committee may impose
such conditions, restrictions, and limitations (including suspending the exercise of the Option and the tolling of any applicable
exercise period during such suspension) on the issuance of Common Stock with respect to the Option unless and until the Committee
determines that such issuance complies with (a) any applicable registration requirements under the Securities Act or the Committee
has determined that an exemption therefrom is available, (b) any applicable listing requirement of any stock exchange on which
the Common Stock is listed, (c) any applicable Company policy or administrative rules, and (d) any other applicable provision
of state, federal, or foreign law, including foreign securities laws where applicable.

 

12.
Miscellaneous.

 

a.
Notices. Any notice that either party hereto may be required or permitted to give to the other shall be in writing and
may be delivered personally, by intraoffice mail, by fax, by electronic mail or other electronic means, or via a postal service,
postage prepaid, to such electronic mail or postal address and directed to such person as the Company may notify the Grantee from
time to time; and to the Grantee at the Grantee’s electronic mail or postal address as shown on the records of the Company
from time to time, or at such other electronic mail or postal address as the Grantee, by notice to the Company, may designate
in writing from time to time.

 

b.
Waiver. The waiver by any party hereto of a breach of any provision of the Award Agreement shall not operate or be construed
as a waiver of any other or subsequent breach.

 

c.
Entire Agreement. The Award Agreement and the Plan constitute the entire agreement between the parties with respect to
the Option. Any prior agreements, commitments, or negotiations concerning the Option are superseded.

 

d.
Binding Effect; Successors. The obligations and rights of the Company under the Award Agreement shall be binding upon and
inure to the benefit of the Company and any successor corporation or organization resulting from the merger, consolidation, sale,
or other reorganization of the Company, or upon any successor corporation or organization succeeding to substantially all of the
assets and business of the Company. The obligations and rights of the Grantee under the Award Agreement shall be binding upon
and inure to the benefit of the Grantee and the beneficiaries, executors, administrators, heirs, and successors of the Grantee.

 

e.
Governing Law; Consent to Jurisdiction; Consent to Venue. The Award Agreement shall be construed and interpreted in accordance
with the internal laws of the State of Delaware without regard to principles of conflicts of law thereof, or principles of conflicts
of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction other than the State of Delaware.
For purposes of resolving any dispute that arises directly or indirectly from the relationship of the parties evidenced by the
Option or the Award Agreement, the parties hereto hereby submit to and consent to the exclusive jurisdiction of the State of California
and agree that any related litigation shall be conducted solely in the courts of Orange County, California or the federal courts
for the United States for the Central District of California where the Award Agreement is made and/or to be performed, and no
other courts.

 

f.
Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way
limit or affect the meaning or interpretation of any of the terms or provisions of the Award Agreement.

 

    	 

    	 

    

 

g.
Amendment. The Award Agreement may be amended at any time by the Committee, provided that no amendment may, without
the consent of the Grantee, materially impair the Grantee’s rights with respect to the Option.

 

h.
Severability. The invalidity or unenforceability of any provision of the Award Agreement shall not affect the validity
or enforceability of any other provision of the Award Agreement, and each other provision of the Award Agreement shall be severable
and enforceable to the extent permitted by law.

 

i.
No Rights to Service. Nothing contained in the Award Agreement shall be construed as giving the Grantee any right to be
retained, in any position, as a director, officer, employee, or consultant of the Company or its Affiliates, or shall interfere
with or restrict in any way the rights of the Company or its Affiliates, which are hereby expressly reserved, to remove, terminate,
or discharge the Grantee at any time for any reason whatsoever or for no reason, subject to the Company’s articles of incorporation,
bylaws, and other similar governing documents and applicable law.

 

j.
Section 409A. It is intended that the Award Agreement and the Option will be exempt from (or in the alternative will comply
with) Code Section 409A, and the Award Agreement shall be administered accordingly and interpreted and construed on a basis consistent
with such intent. This Section 12(j) shall not be construed as a guarantee of any particular tax effect for the Grantee’s
benefits under the Award Agreement and the Company does not guarantee that any such benefits will satisfy the provisions of Code
Section 409A or any other provision of the Code.

 

k.
Further Assurances. The Grantee agrees, upon demand of the Company or the Committee, to do all acts and execute, deliver,
and perform all additional documents, instruments, and agreements that may be reasonably required by the Company or the Committee,
as the case may be, to implement the provisions and purposes of the Award Agreement and the Plan.

 

l.
Confidentiality. The Grantee agrees that the terms and conditions of the Option award reflected in the Award Agreement
are strictly confidential and, with the exception of the Grantee’s counsel, tax advisor, immediate family, or as required
by applicable law, have not and shall not be disclosed, discussed, or revealed to any other persons, entities, or organizations,
whether within or outside Company, without prior written approval of Company. The Grantee shall take all reasonable steps necessary
to ensure that confidentiality is maintained by any of the individuals or entities referenced above to whom disclosure is authorized.

 

By
signing below, the Grantee agrees that the Option is granted under and governed by the terms and conditions of the Plan and the
Award Agreement, as of the Grant Date.

 

	GRANTEE	 	HANCOCK
    JAFFE LABORATORIES, INC.
	 	 	 	 	 
	Sign
    Name:	 	 	Sign
    Name:	 
	 	 	 	 	          
	Print
    Name:	 	 	Print
    Name:	 
	 	 	 	 	 
	 	 	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]